Real-time intelligence on synbio and synbio funding, regulatory milestones, deployments, and policy.
Absci Corporation trades at $2.86 ahead of Q4 earnings on March 24, with investors watching for partnership updates and platform progress.
Read →10x Genomics announces $2.3B CRISPR Brain Atlas collaboration targeting 100M+ neural cell profiles
Read →Absci CEO granted over 2 million equity units with tax withholding, signaling leadership retention amid AI drug discovery push
Read →BTIG reduces price target citing execution risks in Ginkgo's autonomous laboratory transformation strategy
Read →